Innovations in the treatment of anemia in chronic kidney failure
Abstract
Chronic kidney disease (CKD) is a chronic inflammatory process. Inflammation, uremic toxins, deficiency of erythropoietin production, iron deficiency, shortening of erythrocyte lifespan, gastrointestinal losses, etc. lead to anemia in CKD. The prevalence of anemia increases as the CKD stage increases. Hepcidin is an important molecule for the use of iron in anemia. Hypoxia-induced factors (HIF) maintain the continuity of erythropoiesis. This molecule is inactivated by prolyl hydroxylase (PH). HIF-PH inhibitors have come into use in the treatment of anemia due to CKD. This review describes anemia in CKD and the use of HIF PH inhibitors.
Keywords
Chronic kidney disease, anemia, hepcidin, HIF-PH inhibitors.
Supporting Institution
None
References
- Iseki K, Kohagura K. Anemia as a risk factor for chronic kidney disease. Kidney Int Suppl 2007;(107):S4-9.
- Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS One 2014;9(1):e84943.
- Astor BC, Coresh J, Heiss G, Pettitt D, Sarnak MJ. Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2006;151(2):492-500.
- Weiner DE, Tighiouart H, Vlagopoulos PT, Griffith JL, Salem DN, Levey AS, Sarnak MJ. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol 2005;16(6):1803-10.
- Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Lambers Heerspink HJ, Mann JF, Matsushita K, Wen CP. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013;382(9889):339-52.
- Eckardt KU. Anaemia in end-stage renal disease: pathophysiological considerations. Nephrol Dial Transplant 2001;16 Suppl 7:2-8.
- Mathias SD, Blum SI, Sikirica V, Johansen KL, Colwell HH, Tony Okoro T. Symptoms and impacts in anemia of chronic kidney disease. J Patient Rep Outcomes 2020;4(1):64.
- Lasocki S, Longrois D, Montravers P, Beaumont C. Hepcidin and anemia of the critically ill patient: bench to bedside. Anesthesiology 2011;114(3):688-94.
- Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica 2020;105(2):260-72.
- Koury MJ, Haase VH. Anaemia in kidney disease: harnessing hypoxia responses for therapy. Nat Rev Nephrol 2015;11(7):394-410.
